Drug Shortage Report for SODIUM CHLORIDE INJECTION, USP

Last updated on 2021-05-04 History
Report ID 138379
Drug Identification Number 02139510
Brand name SODIUM CHLORIDE INJECTION, USP
Common or Proper name Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) SODIUM CHLORIDE
Strength(s) 234MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 200 mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2021-05-03
Actual start date 2021-05-03
Estimated end date 2021-07-31
Actual end date
Shortage status Actual shortage
Updated date 2021-05-04
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be placing our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL on reduced allocation. Contract customers will be allocated 75% of their historical average monthly volumes, effective Monday, May 3, 2021. We will also be anticipating a backorder for this product effective June 1, 2021 until July 31, 2021. Please note that allocations of our Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 100 mL have been increased to cover the 200mL demand.
Health Canada comments
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v3 2021-05-04 English Compare
v2 2021-04-30 French Compare
v1 2021-04-30 English Compare